ASCOT-BPLA: Summary

1
ASCOT-BPLA Summary
VBWG

• Newer antihypertensive drug regimens should be
  considered in preference to older beta-blocker
  diuretic therapies
• Amlodipine-based regimen was beneficial in
  lowering BP and prevention of CV events compared
  to beta-blocker diuretic-based regimen
• Amlodipine perindopril showed reductions in
• Major CV events 16
• New-onset diabetes 30
• Stroke 23
• Mortality 11
• Improved BP control with amlodipine
  perindopril may explain some, but not all, of the
  benefit

ASCOT results support the use of newer drugs, in
multi-drug combinations, to modify risk factors
and/or metabolic disturbances, especially in
patients with complicated hypertension
Dahlöf B et al. Lancet. 2005366895-906. Poulter
NR et al. Lancet. 2005366907-13.
mean in-trial systolic BP difference 2.7 mm Hg